Cat. No.: HY-N2125

Parishin C

Avis client

Based on 1 Customer Validation

Parishin C is a brain-penetrant major bioactive component found in Gastrodia elata Blume. Parishin C is a 5-HT1A receptor agonist with an EC₅₀ of 34 nM. Parishin C has antipsychotic and neuroprotective effects. Parishin C protects against Aβ-induced long-term potentiation damage and NMDA receptor current impairment. Parishin C reduces oxidative stress, pro-inflammatory cytokine levels, caspase activity, brain water content, and cerebral infarct volume; increases antioxidant enzyme activity and BDNF levels; improves nerve function and histopathological brain damage. Parishin C attenuates phencyclidine-induced immobility time increases, sociability deficits, and visual recognition memory impairment. Parishin C can be used for the research of ischemic stroke, Alzheimer's disease, and schizophrenia-like psychosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.24%
CAS No.: 174972-80-6
Formule: C₃₂H₄₀O₁₉
Masse moléculaire:728.65

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Parishin C Chemical Structure

CAS No.: 174972-80-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]

IL-6

IL-1β

Caspase 3

Caspase 9

NMDA Receptor

Voir tous les produits spécifiques à Isoform 5-HT Receptor :

Voir tous les produits spécifiques à Isoform iGluR :

Voir tous les produits spécifiques à Isoform Caspase :

Voir tous les produits spécifiques à Isoform Interleukin Related :

Voir tous les produits spécifiques à Isoform TNF Receptor :

Voir tous les produits spécifiques à Isoform NF-κB :

In Vitro

Parishin C (10 μM; 0-28 min) does not alter AMPAR and NMDAR currents in primary cultured rat hippocampal pyramidal neurons^[2].
Parishin C (10 μM) does not alter voltage-dependent sodium, potassium, or calcium currents in primary cultured rat hippocampal neurons^[2].
Parishin C (10 μM; 0-20 min) prevents soluble Aβ_1-42 oligomer-induced NMDAR current impairment in primary cultured rat hippocampal pyramidal neurons^[2].
Parishin C (10^-10-10^-5 M) displays high binding affinity for 5-HT₁A receptors in isolated rat hippocampal membranes, with a K_i of 1.54 nM^[3].
Parishin C (10^-10-10^-5 M) acts as a 5-HT₁A receptor full agonist in isolated rat hippocampal membranes, stimulating [³⁵S]GTPγS binding by 78.4% with an EC₅₀ of 34 nM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Parishin C (25-100 mg/kg/day; i.p.; daily; 21 days) exerts dose-dependent neuroprotective effects against middle cerebral artery occlusion-induced ischemic stroke in rats, reducing oxidative stress, inflammation, neuronal apoptosis, and cerebral injury^[1].
Parishin C (20 mg/kg; i.p.; two consecutive days or 10 μM; i.c.v.; 10 minutes before Aβ_1-42 injection) significantly ameliorates soluble Aβ_1-42 oligomer-induced LTP impairment in male Wistar rats^[2].
Parishin C (20 mg/kg; i.p.; single dose) does not alter baseline synaptic transmission or LTP induction in healthy male Wistar rats^[2].
Parishin C (25-100 mg/kg; i.p.; daily; 26 days) dose-dependently attenuates phencyclidine-induced schizophrenia-like behavioral deficits in male C57BL/6J mice via activation of 5-HT₁A receptors^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar (male, 8-10 weeks old, 200-220 g, middle cerebral artery occlusion/reperfusion model)^[1]
Dosage:

25 mg/kg/day; 50 mg/kg/day; 100 mg/kg/day
Administration:

i.p.; daily; 21 days
Result:

Significantly reduced neurological deficit scores in a dose-dependent manner compared to the MCAO-only group.
Significantly reduced brain water conten.
Reduced neuronal necrobiosis and inflammatory cell infiltration.
Significantly increased brain tissue activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px).
Significantly reduced brain tissue malondialdehyde (MDA) levels.
Significantly up-regulated mRNA expression of SOD1, CAT, and GSH-Px.
Significantly reduced brain tissue levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and nuclear factor-kappa B (NF-κB).
Significantly reduced brain tissue activities of Caspase-3 and Caspase-9, and increased brain-derived neurotrophic factor (BDNF) levels.
Significantly reduced cerebral infarct volume.

Animal Model:

Wistar (male, 240-260 g, Alzheimer's disease model induced by i.c.v. injection of soluble Aβ_1-42 oligomers)^[2]
Dosage:

20 mg/kg (i.p. group); 10 μmol/L (i.c.v. group)
Administration:

i.p.; two consecutive days; 10 μM; i.c.v.; 10 minutes before Aβ1-42 injection
Result:

Ameliorated Aβ_1-42-induced LTP impairment significantly, resulting in a population spike amplitude of 179% of baseline (compared to the Aβ_1-42 group's 149%, P < 0.05, n=5).
Protected against Aβ_1-42-induced LTP reduction significantly, resulting in a population spike amplitude of 210% of baseline (compared to the Aβ_1-42 group's 149%, P < 0.05, n=5).

Animal Model:

Phencyclidine-induced schizophrenia-like C57BL/6J (male, 25 g)^[3]
Dosage:

25, 50, 100 mg/kg
Administration:

i.p.; daily; 26 days
Result:

Attenuated PCP-induced increases in immobility time in the forced swimming test in a dose-dependent manner.
Attenuated phencyclidine (PCP)-induced sociability deficits in the social interaction test in a dose-dependent manner.
Attenuated PCP-impaired visual recognition memory in the novel object recognition test in a dose-dependent manner.
Showed all behavioral effects significantly inhibited by co-administration of the 5-HT₁A antagonist WAY 100635 (HY-10349) at 100 mg/kg.

Chemical Information

CAS No. 174972-80-6
Appearance Solid
Masse moléculaire 728.65
Formule C₃₂H₄₀O₁₉
Color White to off-white
SMILES

O[C@H]([C@@H](O)[C@@H]1O)[C@@H](O[C@@H]1CO)OC2=CC=C(COC(CC(C(O)=O)(O)CC(OCC3=CC=C(O[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO)C=C3)=O)=O)C=C2
Structure Classification
- Phenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (137.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 100 mg/mL (137.24 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3724 mL

6.8620 mL

13.7240 mL

5 mM

0.2745 mL

1.3724 mL

2.7448 mL

10 mM

0.1372 mL

0.6862 mL

1.3724 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Wang T, et al. Ameliorative Effect of Parishin C Against Cerebral Ischemia-Induced Brain Tissue Injury by Reducing Oxidative Stress and Inflammatory Responses in Rat Model. Neuropsychiatr Dis Treat. 2021;17:1811-1823. Published 2021 Jun 4. [Content Brief]

[2]. Liu Z, et al. Parishin C's prevention of Aβ 1-42-induced inhibition of long-term potentiation is related to NMDA receptors. Acta Pharm Sin B. 2016;6(3):189-197. [Content Brief]

[3]. Shin EJ, et al. Parishin C attenuates phencyclidine-induced schizophrenia-like psychosis in mice: involvements of 5-HT1A receptor. J Pharmacol Sci. 2010;113(4):404-408. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.3724 mL	6.8620 mL	13.7240 mL	34.3100 mL
	5 mM	0.2745 mL	1.3724 mL	2.7448 mL	6.8620 mL
	10 mM	0.1372 mL	0.6862 mL	1.3724 mL	3.4310 mL
	15 mM	0.0915 mL	0.4575 mL	0.9149 mL	2.2873 mL
	20 mM	0.0686 mL	0.3431 mL	0.6862 mL	1.7155 mL
	25 mM	0.0549 mL	0.2745 mL	0.5490 mL	1.3724 mL
	30 mM	0.0457 mL	0.2287 mL	0.4575 mL	1.1437 mL
	40 mM	0.0343 mL	0.1716 mL	0.3431 mL	0.8578 mL
	50 mM	0.0274 mL	0.1372 mL	0.2745 mL	0.6862 mL
	60 mM	0.0229 mL	0.1144 mL	0.2287 mL	0.5718 mL
	80 mM	0.0172 mL	0.0858 mL	0.1716 mL	0.4289 mL
	100 mM	0.0137 mL	0.0686 mL	0.1372 mL	0.3431 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Parishin C

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Neurotransmitter Receptor Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

5-HT Receptor Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Ion Channel Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Voir tous les produits spécifiques à Isoform 5-HT Receptor

Voir tous les produits spécifiques à Isoform iGluR

Voir tous les produits spécifiques à Isoform Caspase

Voir tous les produits spécifiques à Isoform Interleukin Related

Voir tous les produits spécifiques à Isoform TNF Receptor

Voir tous les produits spécifiques à Isoform NF-κB

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Parishin C Related Classifications

HY-N2125 Related Classifications